HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

S-268019-b COVID-19 vaccine

protein vaccine using S-910823 antigen, which is a modified recombinant spike protein of SARS-CoV-2

Also Known As:

S-268019 COVID-19 vaccine; S-268019-b; S-268019-b vaccine; S268019b COVID-19 vaccine

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Subunit Vaccines: 1839
      - S-268019-b COVID-19 vaccine: 1
    - Viral Vaccines: 462
      - COVID-19 Vaccines: 7607
        S-268019-b COVID-19 vaccine: 1

Experts

1.	Ariyasu, Mari: 1 article (01/2022)
2.	Igarashi, Kenji: 1 article (01/2022)
3.	Ishii, Naoki: 1 article (01/2022)
4.	Kamitani, Akari: 1 article (01/2022)
5.	Omoto, Shinya: 1 article (01/2022)
6.	Sato, Takashi: 1 article (01/2022)
7.	Seki, Naomi M: 1 article (01/2022)
8.	Shibata, Risa Yokokawa: 1 article (01/2022)
9.	Shinkai, Masaharu: 1 article (01/2022)
10.	Shinoda, Masahiro: 1 article (01/2022)

Related Diseases

1.

01/01/2022 - "In conclusion, S-268019-b was safe and showed robust immunogenicity as a booster, supporting its use as COVID-19 booster vaccine."
01/01/2022 - "In this randomized, observer-blinded, phase 2/3 study, S-268019-b (n = 101), a recombinant spike protein vaccine, was analyzed for noninferiority versus BNT162b2 (n = 103), when given as a booster ≥6 months after 2-dose BNT162b2 regimen in Japanese adults without prior SARS-CoV-2 infection. "

Related Drugs and Biologics

1.	Vaccines
2.	Proteins (Proteins, Gene)
3.	BNT162 Vaccine